Literature DB >> 24535562

Association between VKORC1 gene polymorphisms and ischemic cerebrovascular disease in Chinese Han population.

Hua Zhang1, Linyan Yang, Qingchuan Feng, Yujia Fan, Hong Zheng, Ying He.   

Abstract

The vitamin K epoxide reductase subunit 1 gene (VKORC1) plays a key role in vitamin K recycling, and there is a close association between VKORC1 gene single-nucleotide polymorphisms (SNPs) and the required dose of warfarin, an anticoagulant. However, the association between VKORC1 SNPs and ischemic cerebrovascular disease (ICVD) has not been defined. This case-control study involved 370 patients with ICVD and 408 healthy individuals (controls) from Chinese Han population. Two VKORC1 gene SNPs (1639A/G and 1173T/C) were genotyped by PCR-RFLP method. The G allele frequencies of the 1639A/G locus and C allele frequencies of the 1173T/C locus were higher in the ICVD group than in the control group (p = 0.014 and p = 0.008, respectively). Haplotype analysis showed that 1639G-1173C was associated with an increased risk of ICVD (odds ratio (OR) = 1.163, 95 % confidence interval (CI) = 1.137~2.288), while 1639A-1173T was associated with decreased risk of ICVD (OR = 0.620, 95 % CI = 0.437~0.880). Our findings suggested that individuals carrying the 1639G or 1173C allele might be at increased risk for ICVD. Furthermore, the 1639G-1173C haplotype was a risk factor for ICVD, and 1639A-1173T was a protective factor in Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24535562     DOI: 10.1007/s12031-014-0259-x

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  18 in total

1.  Haplotypes vs single marker linkage disequilibrium tests: what do we gain?

Authors:  J Akey; L Jin; M Xiong
Journal:  Eur J Hum Genet       Date:  2001-04       Impact factor: 4.246

2.  A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

Authors:  D Voora; D C Koboldt; C R King; P A Lenzini; C S Eby; R Porche-Sorbet; E Deych; M Crankshaw; P E Milligan; H L McLeod; S R Patel; L H Cavallari; P M Ridker; G R Grice; R D Miller; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-03-03       Impact factor: 6.875

Review 3.  Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle.

Authors:  Johannes Oldenburg; Carville G Bevans; Clemens R Müller; Matthias Watzka
Journal:  Antioxid Redox Signal       Date:  2006 Mar-Apr       Impact factor: 8.401

4.  ENPP1 K121Q polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese population.

Authors:  Miao-Pei Chen; Fu-Mei Chung; Dao-Ming Chang; Jack C-R Tsai; Han-Fen Huang; Shyi-Jang Shin; Yau-Jiunn Lee
Journal:  Rev Diabet Stud       Date:  2006-05-10

5.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Authors:  Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

6.  VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection).

Authors:  Yibo Wang; Weili Zhang; Yuhui Zhang; Yuejin Yang; Lizhong Sun; Shengshou Hu; Jilin Chen; Channa Zhang; Yi Zheng; Yisong Zhen; Kai Sun; Chunyan Fu; Tao Yang; Jianwei Wang; Jing Sun; Haiying Wu; Wayne C Glasgow; Rutai Hui
Journal:  Circulation       Date:  2006-03-20       Impact factor: 29.690

7.  Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study.

Authors:  K Lacut; C Larramendy-Gozalo; G Le Gal; J Duchemin; B Mercier; L Gourhant; D Mottier; L Becquemont; E Oger; C Verstuyft
Journal:  J Thromb Haemost       Date:  2007-10       Impact factor: 5.824

8.  Single nucleotide polymorphisms in the VKORC1 gene and the risk of stroke in the Southern German population.

Authors:  Marie-Luise Arnold; Christoph Lichy; Inge Werner; Alexander Radbruch; Simone Wagner; Caspar Grond-Ginsbach
Journal:  Thromb Haemost       Date:  2008-10       Impact factor: 5.249

9.  Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population.

Authors:  Soo-Chin Lee; Swee-Siang Ng; Johannes Oldenburg; Pei-Yi Chong; Simone Rost; Jia-Yi Guo; Hui-Ling Yap; Sheila Clare Rankin; Hui-Boon Khor; Tiong-Cheng Yeo; Kheng-Siang Ng; Richie Soong; Boon-Cher Goh
Journal:  Clin Pharmacol Ther       Date:  2006-03       Impact factor: 6.875

10.  Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.

Authors:  Ryuhei Saito; Kenji Takeda; Kayo Yamamoto; Akihiko Nakagawa; Hirofumi Aoki; Kosuke Fujibayashi; Minoru Wakasa; Atsushi Motoyama; Mizuho Iwadare; Ryoko Ishida; Nakaba Fujioka; Taketsugu Tsuchiya; Hironobu Akao; Yasuyuki Kawai; Michihiko Kitayama; Kouji Kajinami
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

View more
  4 in total

1.  VKORC1 and CD-14 genetic polymorphisms associate with susceptibility to cardiovascular and cerebrovascular diseases.

Authors:  Jian Du; Zhiguo Zhang; Yuanyuan Ge; Juan Zhen; Jiyan Leng; Jianmeng Wang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  Warfarin dosage adjustment strategy in Chinese population.

Authors:  Zhe Yu; Ying-Long Ding; Fei Lu; Li-Yan Miao; Zhen-Ya Shen; Wen-Xue Ye
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  G-1639A but Not C1173T VKORC1 Gene Polymorphism Is Related to Ischemic Stroke and Its Various Risk Factors in Ukrainian Population.

Authors:  Yevhen I Dubovyk; Viktoriia Yu Harbuzova; Alexander V Ataman
Journal:  Biomed Res Int       Date:  2016-09-15       Impact factor: 3.411

4.  VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.

Authors:  Silvia Misasi; Giuliana Martini; Oriana Paoletti; Stefano Calza; Giovanni Scovoli; Alessandra Marengoni; Sophie Testa; Luigi Caimi; Eleonora Marchina
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.